Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODEL
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
6 EPIDEMIOLOGY
6.1 INCIDENCE OF CIN 1
6.2 INCIDENCE OF CIN 2
6.3 INCIDENCE OF CIN 3
6.4 TREATMENT RATE
6.5 MORTALITY RATE
6.6 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.7 PATEINT TREATMENT SUCCESS RATES
7 INDUSTRY INSIGHTS
8 REGULATORY FRAMEWORK
9 PIPELINE ANALYSIS
9.1 OVERVIEW
9.2 PHASE III CANDIDATES
9.2.1 VGX-3100
9.2.2 OTHERS
9.3 PHASE II CANDIDATES
9.3.1 BLS-ILB-E710C
9.3.2 TERAMEPROCOL
9.3.3 PROGESTERONE
9.3.4 PEMBROLIZUMAB
9.3.5 OTHERS
9.4 PHASE I CANDIDATES
9.5 OTHERS
10 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY TREATMENT
NOTE: THERE ARE NO APPROVED DRUGS FOR CERVICAL INTRAEPITHELIAL NEOPLACIA , BUT HEALTHCARE PRACTITIONERS GENERALLY RECOMMENDED THE HPV REGIME TREATMENT FOR CERVICAL INTRAEPITHELIAL NEOPLASIA PATIENTS AND ALSO FOLLOWING SEGMENT DRUGS WENT FOR VARIOUS RANDOMIZED TRIALS FOR CIN WITH PROMISING RESULTS
10.1 OVERVIEW
10.2 OTC DRUGS
10.2.1 SALICYLIC ACID, BY BRAND
10.2.1.1. WART REMOVER
10.2.1.1.1. MARKET VALUE (USD MN)
10.2.1.1.2. MARKET VOLUME IU)
10.2.1.1.3. AVERAGE SELLING PRICE (USD)
10.2.1.2. MOSCO CORN AND CALLUS REMOVER
10.2.1.2.1. MARKET VALUE (USD MN)
10.2.1.2.2. MARKET VOLUME IU)
10.2.1.2.3. AVERAGE SELLING PRICE (USD)
10.2.1.3. COMPOUND W
10.2.1.3.1. MARKET VALUE (USD MN)
10.2.1.3.2. MARKET VOLUME IU)
10.2.1.3.3. AVERAGE SELLING PRICE (USD)
10.2.1.4. EMERSAL
10.2.1.4.1. MARKET VALUE (USD MN)
10.2.1.4.2. MARKET VOLUME IU)
10.2.1.4.3. AVERAGE SELLING PRICE (USD)
10.2.1.5. WHITFIELDS OINTMENT
10.2.1.5.1. MARKET VALUE (USD MN)
10.2.1.5.2. MARKET VOLUME IU)
10.2.1.5.3. AVERAGE SELLING PRICE (USD)
10.2.1.6. OTHERS
10.2.2 OTHERS
10.3 IMMUNOMODULATORS
10.3.1 TRANS RETINOIC ACID
10.3.1.1. VESANOID
10.3.1.1.1. MARKET VALUE (USD MN)
10.3.1.1.2. MARKET VOLUME IU)
10.3.1.1.3. AVERAGE SELLING PRICE (USD)
10.3.1.2. CAATRA
10.3.1.2.1. MARKET VALUE (USD MN)
10.3.1.2.2. MARKET VOLUME IU)
10.3.1.2.3. AVERAGE SELLING PRICE (USD)
10.3.1.3. TRETENOIN
10.3.1.3.1. MARKET VALUE (USD MN)
10.3.1.3.2. MARKET VOLUME IU)
10.3.1.3.3. AVERAGE SELLING PRICE (USD)
10.3.1.4. OTHERS
10.3.2 INTERFERON ALPHA, BY BRAND
10.3.2.1. INTRON A
10.3.2.1.1. MARKET VALUE (USD MN)
10.3.2.1.2. MARKET VOLUME IU)
10.3.2.1.3. AVERAGE SELLING PRICE (USD)
10.3.2.2. ROFERON A
10.3.2.2.1. MARKET VALUE (USD MN)
10.3.2.2.2. MARKET VOLUME IU)
10.3.2.2.3. AVERAGE SELLING PRICE (USD)
10.3.2.3. ALFERON N
10.3.2.3.1. MARKET VALUE (USD MN)
10.3.2.3.2. MARKET VOLUME IU)
10.3.2.3.3. AVERAGE SELLING PRICE (USD)
10.3.2.4. OTHERS
10.3.3 IMIQUIMOD, BY BRAND
10.3.3.1. ALDARA
10.3.3.1.1. MARKET VALUE (USD MN)
10.3.3.1.2. MARKET VOLUME IU)
10.3.3.1.3. AVERAGE SELLING PRICE (USD)
10.3.3.2. ZYCLARA
10.3.3.2.1. MARKET VALUE (USD MN)
10.3.3.2.2. MARKET VOLUME IU)
10.3.3.2.3. AVERAGE SELLING PRICE (USD)
10.3.3.3. OTHERS
10.4 ANTIVIRALS
10.4.1 CIDOFOVIR (VISTIDE)
10.4.1.1. MARKET VALUE (USD MN)
10.4.1.2. MARKET VOLUME IU)
10.4.1.3. AVERAGE SELLING PRICE (USD)
10.4.2 LOPINAVIR/RITONAVIR (KALETRA)
10.4.2.1. MARKET VALUE (USD MN)
10.4.2.2. MARKET VOLUME IU)
10.4.2.3. AVERAGE SELLING PRICE (USD)
10.4.3 VIDARABINE (VIRA-A)
10.4.3.1. MARKET VALUE (USD MN)
10.4.3.2. MARKET VOLUME IU)
10.4.3.3. AVERAGE SELLING PRICE (USD)
10.5 TRICHLOROACETIC ACID, BY BRAND NAME
10.5.1 TRI CHLOR
10.5.1.1. MARKET VALUE (USD MN)
10.5.1.2. MARKET VOLUME IU)
10.5.1.3. AVERAGE SELLING PRICE (USD)
10.5.2 OTHERS
10.6 PODOFILOX (CODYLOX)
10.6.1 MARKET VALUE (USD MN)
10.6.2 MARKET VOLUME IU)
10.6.3 AVERAGE SELLING PRICE (USD)
11 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY
11.1 OVERVIEW
11.2 ORAL
11.3 TOPICAL
11.4 OTHERS
12 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY DISTRUBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
12.5 OTHERS
13 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.2.1 PRIVATE
13.2.2 PUBLIC
13.3 CLINICS
13.4 SPECIALITY CENTERS
13.5 RESEARCH AND ACADEMIC INSTITUTES
13.6 OTHERS
14 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY GEOGRAPHY
GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.1.1. U.S. CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY TREATMENT
14.1.1.2. U.S. CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
14.1.1.3. U.S. CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY END USER
14.1.1.4. U.S. CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1.2 CANADA
14.1.3 MEXICO
14.1.4 DOMINICAN REPUBLIC
14.1.5 JAMAICA
14.1.6 PANAMA
14.2 EUROPE
14.2.1 GERMANY
14.2.2 FRANCE
14.2.3 U.K.
14.2.4 HUNGARY
14.2.5 LITHUANIA
14.2.6 AUSTRIA
14.2.7 IRELAND
14.2.8 NORWAY
14.2.9 POLAND
14.2.10 ITALY
14.2.11 SPAIN
14.2.12 RUSSIA
14.2.13 TURKEY
14.2.14 NETHERLANDS
14.2.15 SWITZERLAND
14.2.16 REST OF EUROPE
14.3 ASIA-PACIFIC
14.3.1 JAPAN
14.3.2 CHINA
14.3.3 TAIWAN
14.3.4 SOUTH KOREA
14.3.5 INDIA
14.3.6 AUSTRALIA
14.3.7 SINGAPORE
14.3.8 THAILAND
14.3.9 MALAYSIA
14.3.10 INDONESIA
14.3.11 PHILIPPINES
14.3.12 VIETNAM
14.3.13 REST OF ASIA-PACIFIC
14.4 SOUTH AMERICA
14.4.1 BRAZIL
14.4.2 ECUADOR
14.4.3 CHILE
14.4.4 COLOMBIA
14.4.5 VENEZUELA
14.4.6 ARGENTINA
14.4.7 PERU
14.4.8 CURAÇAO
14.4.9 PARAGUAY
14.4.10 URUGUAY
14.4.11 TRINIDAD AND TOBAGO
14.4.12 REST OF SOUTH AMERICA
14.5 MIDDLE EAST AND AFRICA
14.5.1 SOUTH AFRICA
14.5.2 SAUDI ARABIA
14.5.3 UAE
14.5.4 EGYPT
14.5.5 KUWAIT
14.5.6 ISRAEL
14.5.7 BOLIVIA
14.5.8 REST OF MIDDLE EAST AND AFRICA
15 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL CERVICAL INTRAEPITHELIAL NEOPLASIA DRUGS MARKET, COMPANY PROFILE
17.1 COMPANIES BASED ON OFF LABEL DRUGS UDED PRESCRIBED
17.1.1 PERRIGO COMPANY PLC
17.1.1.1. COMPANY OVERVIEW
17.1.1.2. REVENUE ANALYSIS
17.1.1.3. GEOGRAPHIC PRESENCE
17.1.1.4. PRODUCT PORTFOLIO
17.1.1.5. RECENT DEVELOPMENTS
17.1.2 GLENMARK PHARMACEUTICAL INC., USA
17.1.2.1. COMPANY OVERVIEW
17.1.2.2. REVENUE ANALYSIS
17.1.2.3. GEOGRAPHIC PRESENCE
17.1.2.4. PRODUCT PORTFOLIO
17.1.2.5. RECENT DEVELOPMENTS
17.1.3 DR. REDDY’S LABORATORIES LTD
17.1.3.1. COMPANY OVERVIEW
17.1.3.2. REVENUE ANALYSIS
17.1.3.3. GEOGRAPHIC PRESENCE
17.1.3.4. PRODUCT PORTFOLIO
17.1.3.5. RECENT DEVELOPMENTS
17.1.4 TEVA PHARMACEUTICALS USA, INC.
17.1.4.1. COMPANY OVERVIEW
17.1.4.2. REVENUE ANALYSIS
17.1.4.3. GEOGRAPHIC PRESENCE
17.1.4.4. PRODUCT PORTFOLIO
17.1.4.5. RECENT DEVELOPMENTS
17.1.5 BAUSCH HEALTH US, LLC
17.1.5.1. COMPANY OVERVIEW
17.1.5.2. REVENUE ANALYSIS
17.1.5.3. GEOGRAPHIC PRESENCE
17.1.5.4. PRODUCT PORTFOLIO
17.1.5.5. RECENT DEVELOPMENTS
17.1.6 INOVA PHARMACEUTICALS
17.1.6.1. COMPANY OVERVIEW
17.1.6.2. REVENUE ANALYSIS
17.1.6.3. GEOGRAPHIC PRESENCE
17.1.6.4. PRODUCT PORTFOLIO
17.1.6.5. RECENT DEVELOPMENTS
17.1.7 DERMOCARE LABORATORIES GUJARAT LLP
17.1.7.1. COMPANY OVERVIEW
17.1.7.2. REVENUE ANALYSIS
17.1.7.3. GEOGRAPHIC PRESENCE
17.1.7.4. PRODUCT PORTFOLIO
17.1.7.5. RECENT DEVELOPMENTS
17.1.8 MAYNE PHARMA GROUP LIMITED
17.1.8.1. COMPANY OVERVIEW
17.1.8.2. REVENUE ANALYSIS
17.1.8.3. GEOGRAPHIC PRESENCE
17.1.8.4. PRODUCT PORTFOLIO
17.1.8.5. RECENT DEVELOPMENTS
17.1.9 CHIMERIX
17.1.9.1. COMPANY OVERVIEW
17.1.9.2. REVENUE ANALYSIS
17.1.9.3. GEOGRAPHIC PRESENCE
17.1.9.4. PRODUCT PORTFOLIO
17.1.9.5. RECENT DEVELOPMENTS
17.1.10 EMCURE PHARMA UK LTD
17.1.10.1. COMPANY OVERVIEW
17.1.10.2. REVENUE ANALYSIS
17.1.10.3. GEOGRAPHIC PRESENCE
17.1.10.4. PRODUCT PORTFOLIO
17.1.10.5. RECENT DEVELOPMENTS
17.1.11 GRACEWAY PHARMACEUTICALS, LLC
17.1.11.1. COMPANY OVERVIEW
17.1.11.2. REVENUE ANALYSIS
17.1.11.3. GEOGRAPHIC PRESENCE
17.1.11.4. PRODUCT PORTFOLIO
17.1.11.5. RECENT DEVELOPMENTS
17.1.12 AMNEAL PHARMACEUTICALS LLC.
17.1.12.1. COMPANY OVERVIEW
17.1.12.2. REVENUE ANALYSIS
17.1.12.3. GEOGRAPHIC PRESENCE
17.1.12.4. PRODUCT PORTFOLIO
17.1.12.5. RECENT DEVELOPMENTS
17.1.13 STRIDES PHARMA SCIENCE LIMITED
17.1.13.1. COMPANY OVERVIEW
17.1.13.2. REVENUE ANALYSIS
17.1.13.3. GEOGRAPHIC PRESENCE
17.1.13.4. PRODUCT PORTFOLIO
17.1.13.5. RECENT DEVELOPMENTS
17.1.14 TARO PHARMACEUTICAL INDUSTRIES LTD.
17.1.14.1. COMPANY OVERVIEW
17.1.14.2. REVENUE ANALYSIS
17.1.14.3. GEOGRAPHIC PRESENCE
17.1.14.4. PRODUCT PORTFOLIO
17.1.14.5. RECENT DEVELOPMENTS
17.1.15 PADAGIS
17.1.15.1. COMPANY OVERVIEW
17.1.15.2. REVENUE ANALYSIS
17.1.15.3. GEOGRAPHIC PRESENCE
17.1.15.4. PRODUCT PORTFOLIO
17.1.15.5. RECENT DEVELOPMENTS
17.1.16 VIATRIS INC.
17.1.16.1. COMPANY OVERVIEW
17.1.16.2. REVENUE ANALYSIS
17.1.16.3. GEOGRAPHIC PRESENCE
17.1.16.4. PRODUCT PORTFOLIO
17.1.16.5. RECENT DEVELOPMENTS
17.1.17 WOCKHARDT
17.1.17.1. COMPANY OVERVIEW
17.1.17.2. REVENUE ANALYSIS
17.1.17.3. GEOGRAPHIC PRESENCE
17.1.17.4. PRODUCT PORTFOLIO
17.1.17.5. RECENT DEVELOPMENTS
17.1.18 CHEPLAPHARM ARZNEIMITTEL GMBH
17.1.18.1. COMPANY OVERVIEW
17.1.18.2. REVENUE ANALYSIS
17.1.18.3. GEOGRAPHIC PRESENCE
17.1.18.4. PRODUCT PORTFOLIO
17.1.18.5. RECENT DEVELOPMENTS
17.1.19 ALMIRALL, S.A
17.1.19.1. COMPANY OVERVIEW
17.1.19.2. REVENUE ANALYSIS
17.1.19.3. GEOGRAPHIC PRESENCE
17.1.19.4. PRODUCT PORTFOLIO
17.1.19.5. RECENT DEVELOPMENTS
17.2 FUTURE KEY PLAYERS
17.2.1 INOVIO PHARMACEUTICALS
17.2.1.1. COMPANY OVERVIEW
17.2.1.2. REVENUE ANALYSIS
17.2.1.3. GEOGRAPHIC PRESENCE
17.2.1.4. PRODUCT PORTFOLIO
17.2.1.5. RECENT DEVELOPMENTS
17.2.2 BIOLEADERS CORPORATION
17.2.2.1. COMPANY OVERVIEW
17.2.2.2. REVENUE ANALYSIS
17.2.2.3. GEOGRAPHIC PRESENCE
17.2.2.4. PRODUCT PORTFOLIO
17.2.2.5. RECENT DEVELOPMENTS
17.2.3 MERCK SHARP & DOHME
17.2.3.1. COMPANY OVERVIEW
17.2.3.2. REVENUE ANALYSIS
17.2.3.3. GEOGRAPHIC PRESENCE
17.2.3.4. PRODUCT PORTFOLIO
17.2.3.5. RECENT DEVELOPMENTS
17.2.4 TAIHO PHARMACEUTICALS
17.2.4.1. COMPANY OVERVIEW
17.2.4.2. REVENUE ANALYSIS
17.2.4.3. GEOGRAPHIC PRESENCE
17.2.4.4. PRODUCT PORTFOLIO
17.2.4.5. RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
18 RELATED REPORTS
19 CONCLUSION
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
